<DOC>
	<DOCNO>NCT02010827</DOCNO>
	<brief_summary>We want investigate lack glucagon suppression oral glucose tolerance test patient type 2 diabetes contribute patient postprandial hyperglycemia .</brief_summary>
	<brief_title>Endogenous Glucoseproduction Patients With Type 2 Diabetes Mellitus During Oral Glucose iv . Glucose Infusion</brief_title>
	<detailed_description>Patients type 2 diabetes mellitus ( T2DM ) able suppress glucagon secretion meal ingestion glucose . Previous study show gastrointestinal hormone might play role phenomenon . However , yet possible determine whether lack glucagon suppression postprandially result increase endogenous glucose secretion , thus factor patient postprandial hyperglycemia . We aim perform oral glucose tolerance test isoglycemic intravenous glucose infusion without continuous glucagon infusion patient T2DM healthy control subject . The glucagon infusion aim copy inappropriate `` physiological '' glucagon response observe patient T2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Patients T2DM Caucasions 35 year age diet and/or tablettreated T2DM least three month ( diagnosis acording WHO ) Normal haemoglobin Informed consent Healthy Subjects Normal fast plasma glucose ( FPG ) normal HbA1C ( accord World Health Organization ( WHO ) criterion ) Normal haemoglobin Age 35 year Informed consent Inflammatory bowel disease Nephropathy ( serum creatinine &gt; 150 µM and/or albuminuria ) Severe liver disease ( serum alanine aminotransferase ( ALAT ) and/or serum aspartate aminotransferase ( ASAT ) &gt; 3×normal value ) Pregnancy and/or breastfeed Age 80 year Any condition investigator feel would interfere trial participation Patients T2DM Healthy Subjects Diabetes mellitus ( DM ) Prediabetes ( impaired glucose tolerance and/or impair FPG ) First degree relative DM Inflammatory bowel disease Intestinal resection and/or ostomy Nephropathy ( serum creatinine &gt; 150 µM and/or albuminuria Liver disease ( ALAT and/or serum ASAT &gt; 2×normal value ) Pregnancy and/or breastfeed Age 80 year Any condition investigator feel would interfere trial participation</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Endogenous glucose production</keyword>
	<keyword>Incretin hormone</keyword>
</DOC>